Hemophagocytic lymphohistiocytosis presenting with persistent hyperlactatemia: a distinct phenotype Authors: Dan Wang, Litao Guo Published: 2026 To the Editor, Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome that often mimics septic shock in the intensive care unit [1]. Hyperlactatemia in critically ill patients is usually attributed to tissue hypoperfusion, but HLH can also cause severe lactic acidosis through non-hypoxic, cytokine-driven mechanisms [2, 3]. However, the clinical characteristics and prognosis of HLH patients presenting with persistent hyperlactatemia remain poorly described. We systematically searched PubMed, Embase, and Web of Science (up to September 2025) for HLH cases with persistent hyperlactatemia (lactate ≥ 2.5 mmol/L, excluding type A lactic acidosis). We also included four cases from our institution. HLH diagnosis was confirmed by meeting ≥ 5 HLH-2004 criteria or an explicit diagnostic statement [4]. Data were extracted independently by two reviewers. Detailed search strategies for each database are provided in Supplementary Tables S1 and S3, and the literature screening and selection process is detailed in Supplementary Figure S1. A total of 68 patients (median age 46 years, 58.8% male) were identified. In-hospital mortality was 61.3% (38/62). Malignancy (47.1%, predominantly B-cell lymphoma) and infection (51.5%, predominantly EBV/CMV) were the most common triggers. Notably, 44.1% of patients were initially suspected of having sepsis, and all 50 patients with documented treatment records received broad-spectrum antibiotics. The median peak lactate was 16.36 mmol/L. A key laboratory finding was markedly elevated ferritin: among patients with available data, median ferritin was 14,805 µg/L (IQR 6,579–45,335), and all 60 patients with documented ferritin levels had values ≥ 500 µg/L. Peak lactate levels did not differ significantly between survivors and non-survivors (13.97 ± 6.62 vs. 18.07 ± 8.10 mmol/L, p = 0.492). However, rapid lactate decline within 72 h after treatment initiation was strongly associated with survival. Among patients with documented lactate trends, rapid decline was observed in all 11 survivors (100%) but in only 5 of 18 non-survivors (27.8%) (p < 0.001). In addition, the time from symptom onset to diagnosis was three times longer in non-survivors (21.0 vs. 7.0 days, p = 0.019), and ICU admission was more frequent among non-survivors (97.4% vs. 79.2%, p = 0.028). Detailed clinical characteristics and prognostic data are provided in the Supplementary Information (Tables S2, S4). These findings define a distinct, high-mortality HLH phenotype characterized by extreme hyperlactatemia (median peak, 16 mmol/L) and frequent initial misdiagnosis as sepsis (44.1%). Marked hyperferritinemia was a consistent feature [5]. The most clinically valuable observation is that early lactate decline (within 72 h) is a strong prognostic indicator within this phenotype, whereas the absolute peak lactate level is not. This has immediate practical implications: in patients with suspected or confirmed HLH, failure of lactate to decrease promptly predicts poor outcomes and should prompt diagnostic re-evaluation and consideration of more aggressive therapy. Notably, rapid lactate decline does not guarantee survival, as 5 of 18 non-survivors also achieved it, highlighting that other factors—such as irreversible organ damage or underlying disease progression—contribute to mortality. Diagnostic delay appears to be a major driver of treatment failure. Limitations include the retrospective design, potential selection bias, and incomplete data reporting. The diversity of treatment regimens precludes comparisons of specific therapies. In conclusion, HLH with severe hyperlactatemia represents a high-risk, under-recognized phenotype. Dynamic lactate monitoring, specifically early lactate decline within 72 h after treatment initiation, may provide useful prognostic information. Clinicians encountering patients with persistent hyperlactatemia in the setting of other HLH features (such as extreme hyperferritinemia or cytopenias) should consider this phenotype. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1. Table S1–S4. Supplementary Material 1. Table S1–S4. Supplementary Material 2. Figure S1. PRISMA flowchart of literature screening and case selection. From 698 initial records, 136 full-text articles were assessed. After exclusions, 64 patients from 59 publications were combined with 4 local cases, resulting in a final cohort of 68 patients. Supplementary Material 2. Figure S1. PRISMA flowchart of literature screening and case selection. From 698 initial records, 136 full-text articles were assessed. After exclusions, 64 patients from 59 publications were combined with 4 local cases, resulting in a final cohort of 68 patients. Supplementary Figure S1 Supplementary Figure S1 Supplementary Materials Supplementary Materials